-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 15th Gilead/Noor and Nord jointly published the results of the Phase II proof-of-concept study.
the 5-arm, 24-week phase II clinical study, which included 108 subjects, evaluated noro and Nord's glutatrogin-like peptide-1 (GLP-1) subject agonist Somalutide in combination with Gilead The efficacy and safety of the steroid faniol X-subject (FXR) astigtor cilofexo and or Gilead acetyl coenzyme A carbohydrase (ACC) inhibitor firsocostat for the treatment of non-alcoholic fatty hepatitis (NASH).
results were presented at the 71st Annual Meeting/Virtual Meeting of the American Association for the Study of Hepatology (AASLD).
the study reached its main clinical endpoint, NASH patients with mild and moderate hepatic fibrosis were well-resistant to all treatment options.
most common adverse events (AEs) are gastrointestinal reactions.
itching symptoms in patients in the cilofexor group.
all groups had between 5% and 14% of patients who stopped taking drugs because of AEs. After 24 weeks of
treatment, an ex post-mortem analysis of the exploratory therapeutic endpoint of the evaluation of biomarkers of liver health showed a statistically significant improvement in the liver fat degeneration (measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver injury (serum alanine amino transferase (ALT)) indicators compared to the somalutide monotherapy group.
Cilofexo is a nonsteroidal funiol X-subject (FXR) exciter developed jointly by Gilead and Phenex Pharma, and the adaptations currently being developed are as follows: Source: Pharma GoFirsocostat, a acetyl coenzyme A carbidease (ACC) inhibitor developed jointly by Gilead and Nimbus Therapeutics. ACC is the speed limit enzyme in fat synthesis process from the beginning, NASH patients with significantly faster body fat rebirth, so ACC inhibitors can reduce lipid synthesis or accelerate its decomposition.